Organon's SWOT analysis: women's health leader faces biosimilar growth, LOE challenges
Organon & Co. (NYSE:OGN), a global healthcare company spun off from Merck (NSE:PROR) in 2021, has established itself as a leader in women's health while expanding its presence in biosimilars and ...
Organon & Co. (OGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...
Organon targets $1B in Nexplanon revenue for 2025 while advancing Vtama expansion
Vtama is projected to contribute $150 million in 2025 revenue, supported by its new label approval for atopic dermatitis. Nexplanon is expected to reach at least $1 billion in revenue for 2025. Q4 ...
pharmaphorum5d
So it begins: Next Humira biosimilars launch in US
So it was that Saturday 1st July was a busy day. Organon and Samsung Bioepsis were first to launch biosimilar Hadlima (adalimumab-bwwd) that day, at the sale price of $1,038 per carton containing ...
pharmaphorum3d
Interchangeable high-concentration Humira approved in US
Most are, however, working to get interchangeable status for their biosimilars, and three of them – Organon/Samsung Bioepis’ Hadlima, Sandoz’ Hyrimoz, and Celltrion’s Yuflyma – already ...
Business Wire8d
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
Biosimilars revenue declined 18% on both an ... pressure in the U.S. Performance was partially offset by sales of Hadlima® (adalimumab-bwwd) that have continued to ramp up since its July 2023 ...